LHRH Targeted Chonderosomes of Mitomycin C in Breast Cancer: An In Vitro/ In Vivo Study

Author(s): Jaleh Varshosaz*, Nasim Sarrami, Mahmoud Aghaei, Mehdi Aliomrani, Reza Azizi

Journal Name: Anti-Cancer Agents in Medicinal Chemistry
(Formerly Current Medicinal Chemistry - Anti-Cancer Agents)

Volume 19 , Issue 11 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Mitomycin C (MMC) is an anti-cancer drug used for the treatment of breast cancer with limited therapeutic index, extreme gastric adverse effects and bone marrow suppression. The purpose of the present study was the preparation of a dual-targeted delivery system of MMC for targeting CD44 and LHRH overexpressed receptors of breast cancer.

Methods: MMC loaded LHRH targeted chonderosome was prepared by precipitation method and was characterized for their physicochemical properties. Cell cycle arrest and cytotoxicity tests were studied on cell lines of MCF-7, MDA-MB231 and 4T1 (as CD44 and LHRH positive cells) and BT-474 cell line (as CD44 negative receptor cells). The in vivo histopathology and antitumor activity of MMC-loaded chonderosomes were compared with free MMC in 4T1 cells inducing breast cancer in Balb-c mice.

Results: MMC loaded LHRH targeted chonderosomes caused 3.3 and 5.5 fold more cytotoxicity on MCF-7 and 4T1 cells than free MMC at concentrations of 100μM and 10μM, respectively. However, on BT-474 cells the difference was insignificant. The cell cycle test showed no change for MMC mechanism of action when it was loaded in chonderosomes compared to free MMC. The in vivo antitumor studies showed that MMC loaded LHRH targeted chonderosomes were 6.5 fold more effective in the reduction of tumor volume than free MMC with the most severe necrosis compared to non-targeted chonderosomes in pathological studies on harvested tumors.

Conclusion: The developed MMC loaded LHRH targeted chonderosomes were more effective in tumor growth suppression and may be promising for targeted delivery of MMC in breast cancer.

Keywords: Mitomycin C, busereline acetate, chonderosome, breast cancer, antitumor activity, LHRH receptor.

[1]
Olsson, E.; Honeth, G.; Bendahl, P.O.; Saal, L.H.; Gruvberger-Saal, S.; Ringnér, M.; Vallon-Christersson, J.; Jönsson, G.; Holm, K.; Lövgren, K.; Fernö, M.; Grabau, D.; Borg, Å.; Hegardt, C. CD44 isoforms are heterogeneously expressed in breast cancer and correlate with tumor subtypes and cancer stem cell markers. BMC Cancer, 2011, 11(1), 418.
[2]
Louderbough, J.M.; Schroeder, J.A. Understanding the dual nature of CD44 in breast cancer progression. Mol. Cancer Res., 2011, 9(12), 1573-1586.
[3]
Shao, J.; Fan, W.; Ma, B.; Wu, Y. Breast cancer stem cells expressing different stem cell markers exhibit distinct biological characteristics. Mol. Med. Rep., 2016, 14(6), 4991-4998.
[4]
Yan, W.; Chen, Y.; Yao, Y.; Zhang, H.; Wang, T. Increased invasion and tumorigenicity capacity of CD44+/CD24- breast cancer MCF7 cells in vitro and in nude mice. Cancer Cell Int., 2013, 13(1), 62.
[5]
Hiscox, S.; Baruah, B.; Smith, C.; Bellerby, R.; Goddard, L.; Jordan, N.; Poghosyan, Z.; Nicholson, R.I.; Barrett-Lee, P.; Gee, J. Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan. BMC Cancer, 2012, 12, 458.
[6]
Shirure, V.S.; Liu, T.; Delgadillo, L.F.; Cuckler, C.M.; Tees, D.F.; Benencia, F.; Goetz, D.J.; Burdick, M.M. CD44 variant isoforms expressed by breast cancer cells are functional E-selectin ligands under flow conditions. Am. J. Physiol. Cell Physiol., 2015, 308(1), C68-C78.
[7]
Ponta, H.; Wainwright, D.; Herrlich, P. Molecules in focus the CD44 protein family. Int. J. Biochem. Cell Biol., 1998, 30(3), 299-305.
[8]
Murai, T.; Sougawa, N.; Kawashima, H.; Yamaguchi, K.; Miyasaka, M. CD44-chondroitin sulfate interactions mediate leukocyte rolling under physiological flow conditions. Immunol. Lett., 2004, 93(2-3), 163-170.
[9]
Fujimoto, T.; Kawashima, H.; Tanaka, T.; Hirose, M.; Toyama-Sorimachi, N.; Matsuzawa, Y.; Miyasaka, M. CD44 binds a chondroitin sulfate proteoglycan, aggrecan. Int. Immunol., 2001, 13(3), 359-366.
[10]
Nagy, A.; Schally, A.V. Cytotoxic analogs of luteinizing hormone-releasing hormone (LHRH): A new approach to targeted chemotherapy. Drugs Future, 2002, 27(4), 359.
[11]
Ben-Yehudah, A.; Lorberboum-Galski, H. Targeted cancer therapy with gonadotropin-releasing hormone chimeric proteins. Expert Rev. Anticancer Ther., 2004, 4(1), 151-161.
[12]
Leuschner, C.; Enright, F.M.; Gawronska-Kozak, B.; Hansel, W. Human prostate cancer cells and xenografts are targeted and destroyed through luteinizing hormone releasing hormone receptors. Prostate, 2003, 56(4), 239-249.
[13]
Qi, L.; Nett, T.M.; Allen, M.C.; Sha, X.; Harrison, G.S.; Frederick, B.A.; Crawford, E.D.; Glode, L.M. Binding and cytotoxicity of conjugated and recombinant fusion proteins targeted to the gonadotropin-releasing hormone receptor. Cancer Res., 2004, 64(6), 2090-2095.
[14]
Tambe, P.; Kumar, P.; Paknikar, K.M.; Gajbhiye, V. Decapeptide functionalized targeted mesoporous silica nanoparticles with doxorubicin exhibit enhanced apoptotic effect in breast and prostate cancer cells. Int. J. Nanomedicine, 2018, 13, 7669-7680.
[15]
Varshosaz, J.; Hassanzadeh, F.; Aliabadi, H.S.; Rabbani-Khoraskani, F.; Mirian, M.; Behdadfar, B. Targeted delivery of doxorubicin to breast cancer cells by magnetic LHRH chitosan bioconjugated nanoparticles. Int. J. Biol. Macromol., 2016, 93, 1192-1205.
[16]
Ekins, S.; Kim, R.B.; Leake, B.F.; Dantzig, A.H.; Schuetz, E.G.; Lan, L.; Yasuda, K.; Shepard, R.L.; Winter, M.A.; Schuetz, J.D.; Wikel, J.H.; Wrighton, S.A. Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. Mol. Pharmacol., 2002, 61(5), 964-973.
[17]
Maitra, R.; Halpin, P.A.; Karlson, K.H.; Page, R.L.; Paik, D.Y.; Leavitt, M.O.; Moyer, B.D.; Stanton, B.A.; Hamilton, J.W. Differential effects of mitomycin C and doxorubicin on P-glycoprotein expression. Biochem. J., 2001, 355(3), 617-624.
[18]
Matsumoto, S.; Yamamoto, A.; Takakura, Y.; Hashida, M.; Tanigawa, N.; Sezaki, H. Cellular interaction and in vitro antitumor activity of mitomycin C-dextran conjugate. Am. Ass. Cancer Res., 1986, 46(9), 4463-4468.
[19]
Jia, M.; Li, Y.; Yang, X.; Huang, Y.; Wu, H.; Huang, Y.; Lin, J.; Li, Y.; Hou, Z.; Zhang, Q. Development of both methotrexate and mitomycin C loaded PEGylated chitosan nanoparticles for targeted drug codelivery and synergistic anticancer effect. ACS Appl. Mater. Interfaces, 2014, 6(14), 11413-11423.
[20]
Nomura, T.; Saikawa, A.; Morita, S. Sakaeda (ne Kakutani), T.; Yamashita, F.; Honda, K.; Yoshinobu, T.; Hashida, M. Pharmacokinetic characteristics and therapeutic effects of mitomycin C-dextran conjugates after intratumoural injection. J. Control. Release, 1998, 52(3), 239-252.
[21]
Cheung, R.Y.; Ying, Y.; Rauth, A.M.; Marcon, N.; Wu, X.Y. Biodegradable dextran-based microspheres for delivery of anticancer drug mitomycin C. Biomaterials, 2005, 26(26), 5375-5385.
[22]
Cummings, J.; Allan, L.; Smyth, J.F. Encapsulation of mitomycin C in albumin microspheres markedly alters pharmacokinetics, drug quinone reduction in tumour tissue and antitumour activity: Implications for the drugs’ in vivo mechanism of action. Biochem. Pharmacol., 1994, 47(8), 1345-1356.
[23]
Ishiki, N.; Onishi, H.; Machida, Y. Evaluation of antitumor and toxic side effects of mitomycin C–estradiol conjugates. Int. J. Pharm., 2004, 279(1-2), 81-93.
[24]
Onishi, H.; Takahashi, H.; Yoshiyasu, M.; Machida, Y. Preparation and in vitro properties of N-succinylchitosan- or carboxymethylchitin-mitomycin C conjugate microparticles with specified size. Drug Dev. Ind. Pharm., 2001, 27(7), 659-667.
[25]
Xi-Xiao, Y.; Jan-Hai, C.; Shi-Ting, L.; Dan, G.; Xv-Xin, Z. Polybutylcyanoacrylate nanoparticles as a carrier for mitomycin C in rabbits bearing VX2-liver tumor. Regul. Toxicol. Pharmacol., 2006, 46(3), 211-217.
[26]
Sarısözen, C.; Aktaş, Y.; Mungan, A.; Bilensoy, E. Bioadhesive coated poly-epsilon-caprolactone nanoparticles loaded with Mitomycin C for the treatment of superficial bladder tumors. Eur. J. Pharm. Sci., 2007, 32(1), S36.
[27]
Li, Y.; Wu, H.; Jia, M.; Cui, F.; Lin, J.; Yang, X.; Wang, Y.; Dai, L.; Hou, Z. Therapeutic effect of folate-targeted and PEGylated phytosomes loaded with a mitomycin C–soybean phosphatidyhlcholine complex. Mol. Pharm., 2014, 11(9), 3017-3026.
[28]
Zhang, R.X.; Cai, P.; Zhang, T.; Chen, K.; Li, J.; Cheng, J.; Pang, K.S.; Adissu, H.A.; Rauth, A.M.; Wu, X.Y. Polymer-lipid hybrid nanoparticles synchronize pharmacokinetics of co-encapsulated doxorubicin-mitomycin C and enable their spatiotemporal co-delivery and local bioavailability in breast tumor. Nanomed Nanotechnol. Biol. Med, 2016, 12(5), 1279-1290.
[29]
Erdoğar, N.; İskit, A.B.; Mungan, N.A.; Bilensoy, E. Prolonged retention and in vivo evaluation of cationic nanoparticles loaded with Mitomycin C designed for intravesical chemotherapy of bladder tumours. J. Microencapsul., 2012, 29(6), 576-582.
[30]
Kranz, H.; Bodmeier, R. A novel in situ forming drug delivery system for controlled parenteral drug delivery. Int. J. Pharm., 2007, 332(1-2), 107-114.
[31]
Kakar, S.S.; Jin, H.; Hong, B.; Eaton, J.W.; Kang, K.A. LHRH receptor targeted therapy for breast cancer. Adv. Exp. Med. Biol., 2008, 614, 285-296.
[32]
Seitz, S.; Buchholz, S.; Schally, A.V.; Weber, F.; Klinkhammer-Schalke, M.; Inwald, E.C.; Perez, R.; Rick, F.G.; Szalontay, L.; Hohla, F.; Segerer, S.; Kwok, C.W.; Ortmann, O.; Engel, J.B. Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125. BMC Cancer, 2014, 14, 847.
[33]
Song, S.; Qi, H.; Xu, J.; Guo, P.; Chen, F.; Li, F.; Yang, X.; Sheng, N.; Wu, Y.; Pan, W. Hyaluronan-based nanocarriers with CD44-overexpressed cancer cell targeting. Pharm. Res., 2014, 31(11), 2988-3005.
[34]
Taheri, A.; Dinarvand, R.; Ahadi, F.; Khorramizadeh, M.R.; Atyabi, F. The in vivo antitumor activity of LHRH targeted methotrexate-human serum albumin nanoparticles in 4T1 tumor-bearing Balb/c mice. Int. J. Pharm., 2012, 431(1-2), 183-189.
[35]
Jin, J.; Krishnamachary, B.; Mironchik, Y.; Kobayashi, H.; Bhujwalla, Z.M. Phototheranostics of CD44-positive cell populations in triple negative breast cancer. Sci. Rep., 2016, 6, 27871.
[36]
Hou, Z.; Wei, H.; Wang, Q.; Sun, Q.; Zhou, C.; Zhan, C.; Tang, X.; Zhang, Q. New method to prepare mitomycin C loaded PLA-nanoparticles with high drug entrapment efficiency. Nanoscale Res. Lett., 2009, 4(7), 732.
[37]
Li, Y.; Wu, H.; Yang, X.; Jia, M.; Li, Y.; Huang, Y.; Lin, J.; Wu, S.; Hou, Z. Mitomycin C-soybean phosphatidylcholine complex-loaded self-assembled PEG-lipid-PLA hybrid nanoparticles for targeted drug delivery and dual-controlled drug release. Mol. Pharm., 2014, 11(8), 2915-2927.
[38]
Hou, Z.; Sun, Q.; Wang, Q.; Han, J.; Wang, Y.; Zhang, Q. In vitro and in vivo evaluation of novel implantable collagen-chitosan-soybean phosphatidylcholine composite film for the sustained delivery of mitomycin C. Drug Dev. Res., 2009, 70(3), 206-213.
[39]
Shuhendler, A.J.; Cheung, R.Y.; Manias, J.; Connor, A.; Rauth, A.M.; Wu, X.Y. A novel doxorubicin-mitomycin C co-encapsulated nanoparticle formulation exhibits anti-cancer synergy in multidrug resistant human breast cancer cells. Breast Cancer Res. Treat., 2010, 119(2), 255-269.
[40]
Yi, Y.; Li, Y.; Wu, H.; Jia, M.; Yang, X.; Wei, H.; Lin, J.; Wu, S.; Huang, Y.; Hou, Z.; Xie, L. Single- Single-step assembly of polymer-lipid hybrid nanoparticles for mitomycin C delivery. Nanoscale Res. Lett., 2014, 9(1), 560.
[41]
Segal-Abramson, T.; Kitroser, H.; Levy, J.; Schally, A.V.; Sharoni, Y. Direct effects of luteinizing hormone-releasing hormone agonists and antagonists on MCF-7 mammary cancer cells. Proc. Natl. Acad. Sci. USA, 1992, 89(6), 2336-2339.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 19
ISSUE: 11
Year: 2019
Page: [1405 - 1417]
Pages: 13
DOI: 10.2174/1871520619666190415165849
Price: $65

Article Metrics

PDF: 21
HTML: 2